Novotech

Tom Hickey, Director-Therapeutic Strategy at Novotech, was recently featured in an interview with Anit Kankar from BioSpectrum Asia, a leading source of biotechnology and health sciences in the APAC region. In his interview, Tom offers his perspective on the evolving landscape of Hepatitis B clinical trials, highlighting one of field’s most pressing challenges—patient recruitment and retention in chronic Hepatitis B trials. Drawing on his extensive therapeutic and strategic expertise, Tom discusses practical, forward-thinking solutions designed to address these hurdles—ultimately helping to accelerate trial timelines and improve outcomes for both sponsors and patients. Read the full article: https://lnkd.in/dP6SGA7p #Novotech #ClinicalTrials #HepatitisB

New Report: How Infectious Disease Clinical Trials Are Shaping Global Health Infectious diseases account for approximately 14 million deaths each year, disproportionately impacting low- and middle-income countries. Novotech’s latest report explores how the clinical trial landscape is evolving to meet these challenges and drive global health progress. Key insights: 🔹Nearly 2,000 infectious disease trials initiated since 2020 🔹Asia-Pacific leads with 70% CAGR; North America follows with 52% 🔹Over 900 trials in viral infections including COVID-19, HIV/AIDS, hepatitis B, and RSV 🔹Emerging innovations: AI-driven discovery and decentralized trial models 🔹Regulatory harmonization and platform trials accelerating development timelines 🔹Antimicrobial resistance remains an urgent priority Download the full report to explore trends, strategies, and opportunities in infectious disease clinical development: https://lnkd.in/dX2MWJtT #InfectiousDisease #Novotech #GlobalHealth

Novotech recently attended the NECTA Drug Development Meeting 2025 in Sydney, where industry leaders gathered to discuss the future of drug development across the Asia-Pacific region. Our team had the opportunity to connect with biotech innovators, engage in productive discussions, and share expert insights on: • Global Phase I strategies • Theranostics in clinical trials • Advancing early-phase clinical trials in Australia Thank you to everyone who took the time to meet with us. If we missed you, we’d welcome the opportunity to connect. Contact us to learn how Novotech’s early-phase expertise can support your clinical development strategy: https://lnkd.in/dKXKvtNh Julie Gargano, Joanne Hawking, Malia Rogers, Passant Zaki, Dr. Yifan Chen, MD/ PhD, Javiera Kaiser, Dhanya Nair #Novotech #DrugDevelopment #EarlyPhase

Bladder cancer remains a major global health concern, with primary care physicians playing a vital role in early detection and patient outcomes. In her latest article, Sarah Rose Anderson, Oncology Strategy Lead at Novotech, explores: 🔹 The latest therapeutic breakthroughs (immunotherapy, CAR-T, gene therapy) 🔹 The role of clinical trials in driving innovation 🔹 Global disparities in care access 🔹 Practical strategies for PCPs and researchers Read how innovation, collaboration, and education can reshape the future of bladder cancer management. https://lnkd.in/dSRBmDdv #Oncology #BladderCancer #Novotech

Big news from Novotech! We’re excited to share that affiliates of GIC and Temasek have signed binding agreements to acquire a significant stake in Novotech. Existing investor TPG will also reinvest through its TPG Asia fund. This capital will fuel our next phase of growth — driving global expansion, organic scale, and transformative M&A opportunities. It’s a major milestone in our journey to become the first truly global biotech-focused CRO. https://lnkd.in/dqTbq8Yt Dr. John Moller, Michael Stibilj, Dr. Judith Ng-Cashin, M.D., Barry Murphy, Veronica Holloway, Angela Edwardson, Hansong (Andy) Liu, Rick Farris, Dr. Yooni Kim #BiotechCRO #GlobalGrowth #Novotech

The 2025 CMAC Annual Meeting successfully concluded on March 20th at the Suzhou International Expo Center. It was an energizing few days of collaboration, insight, and innovation. Catherine Xu, Associate Director and Operational Strategy Lead at Novotech, delivered an insightful presentation at the Challenges and Strategies in Globally Coordinated Clinical Development forum. She shared practical strategies for designing global RNA drug clinical trials and offered a forward-looking update on the evolving RNA therapy landscape. Catherine also participated in the roundtable discussion on "Simultaneous Introduction and Innovative Globalization: Strategies for Biopharmaceutical Companies' Globalization and High-Value Patent Layout". This year’s CMAC meeting was a great opportunity to spotlight Novotech’s growing leadership in RNA drug development and our ability to deliver globally coordinated, clinical trials. Backed by our global reach and experienced team, Novotech is well-equipped to efficiently drive the design and implementation of multinational clinical trials, facilitating the rapid market entry of innovative therapies. Didn’t get a chance to connect with our team? Fill out the form, and one of our clinical development experts will reach out to explore how we can support your goals. https://lnkd.in/gEDmZmJE #CMAC2025 #RNAtherapy #Novotech

Novotech has been awarded Best Contract Research Organization in Australia at the Asia-Pacific Biopharma Excellence Awards 2025. This industry-voted recognition reflects Novotech’s commitment to clinical trial excellence and leadership in supporting biotech and pharma sponsors. As Australia continues to emerge as a hub for early-phase trials, more companies are choosing Novotech as their trusted partner to launch and accelerate their studies. We appreciate the continued support of the industry and remain committed to advancing clinical research throughout Australia, the Asia-Pacific region and globally. Learn more about our award-winning clinical trial capabilities: https://lnkd.in/dQdAQp2g #ClinicalTrials #Novotech #ABEA2025

Novotech participated in the Clinical Trials Festival Asia 2025 in Singapore, contributing to discussions on clinical trial design, regulatory strategy, and decentralized trial execution across the Asia-Pacific region. Chris Chong, Senior Director – Clinical Services, delivered a presentation on Shaping Clinical Trials: AI-Driven Optimization, highlighting the role of AI in improving trial efficiency, design, and execution. If you were unable to attend or did not have the opportunity to connect with Novotech at the event, feel free to contact us to discuss your development programs. https://lnkd.in/gEDmZmJE Bableen S., Chris Chong #Novotech #Biopharma #DrugDevelopment

Novotech, and Acrostar have signed a strategic MOU with Kyungpook National University Hospital (KNUH), to advance clinical trials in regenerative medicine. The partnership is strategically aligned with the upcoming Advanced Regenerative Bio Act set to take effect in February 2025, emphasizing advancements in regenerative medicine. Initial trials will commence at the Advanced Clinical Trials Center, with plans to expand to KNUH’s Main Campus and Chilgok Branch for later-stage studies. Both campuses, designated as Advanced Regenerative Medicine Centers, will oversee clinical trials targeting a range of diseases, bringing innovative treatments to patients. Together, Novotech, Acrostar, and KNUH will drive the future of regenerative medicine through high-quality clinical trials and global collaboration. https://lnkd.in/dvVUXdwQ #RegenerativeMedicine #Novotech #KNUH

Thank you to everyone who connected with Novotech at the 4th BioCentury-BayHelix East-West Summit in Singapore. As part of our discussions on biotech globalization and precision medicine, we engaged with industry leaders on Asia-Pacific’s role in shaping global drug development. Dr. Yooni Kim, Managing Director – APAC, shared key insights at the R&D Roundtable on Precision Medicine, highlighting the challenges Asia-based companies face when expanding precision medicine clinical trials to the US and EU. She also discussed strategies for overcoming these challenges and key considerations for ensuring the successful execution of precision medicine clinical trials on a global scale. If you did not attend or did not have the chance to meet us, we are available to connect. Schedule a meeting to explore how Novotech’s regional expertise can support your biotech expansion strategies. https://lnkd.in/gEDmZmJE Chris Chong, Bableen S., Wen Fen C., Junru Tao #Biopharma #Novotech #PrecisionMedicine